BACKGROUND AND PURPOSE: Bone marrow-derived mononuclear cells (MNCs) are an investigational autologous cell-based therapy for acute ischemic stroke. Both intravenous (IV) and intra-arterial (IA) administration routes have been used in clinical trials. However, the route of administration to optimize the effect of MNCs is unknown. In this study, we compared the effect of IV versus IA route of administration of MNCs in the rat stroke model. METHODS: Long Evans rats were subjected to transient middle cerebral artery occlusion. At 24 hours after stroke, animals were randomly assigned to receive autologous bone marrow-derived MNCs using either the IV or IA delivery route. IV saline served as control. One million cells/kg (low dose) and 30 million cells/kg (high dose) were assessed. Neurological testing, cavity size, serum cytokines, neuroregenerative end points, and MNC biodistribution were evaluated. RESULTS: High-dose MNCs improved functional recovery, reduced lesion size and proinflammatory cytokines, and increased vessel density and neurogenesis markers compared with saline treatment (P<0.05). However, there were no significant differences between IV and IA MNC-treated groups, although IV MNCs reduced serum interleukin-1β levels compared with IA MNCs (P<0.05). IA MNCs at high dose led to a greater number of cells in the brain at 1 and 6 hours after injection but not in the lungs and spleen. Low-dose MNCs (by IV or IA) did not improve any functional or structural end point compared with saline. CONCLUSIONS: At low and high doses of MNCs, we found that IV or IA achieves similar structural and functional outcomes after stroke.
BACKGROUND AND PURPOSE: Bone marrow-derived mononuclear cells (MNCs) are an investigational autologous cell-based therapy for acute ischemic stroke. Both intravenous (IV) and intra-arterial (IA) administration routes have been used in clinical trials. However, the route of administration to optimize the effect of MNCs is unknown. In this study, we compared the effect of IV versus IA route of administration of MNCs in the ratstroke model. METHODS: Long Evans rats were subjected to transient middle cerebral artery occlusion. At 24 hours after stroke, animals were randomly assigned to receive autologous bone marrow-derived MNCs using either the IV or IA delivery route. IV saline served as control. One million cells/kg (low dose) and 30 million cells/kg (high dose) were assessed. Neurological testing, cavity size, serum cytokines, neuroregenerative end points, and MNC biodistribution were evaluated. RESULTS: High-dose MNCs improved functional recovery, reduced lesion size and proinflammatory cytokines, and increased vessel density and neurogenesis markers compared with saline treatment (P<0.05). However, there were no significant differences between IV and IA MNC-treated groups, although IV MNCs reduced serum interleukin-1β levels compared with IA MNCs (P<0.05). IA MNCs at high dose led to a greater number of cells in the brain at 1 and 6 hours after injection but not in the lungs and spleen. Low-dose MNCs (by IV or IA) did not improve any functional or structural end point compared with saline. CONCLUSIONS: At low and high doses of MNCs, we found that IV or IA achieves similar structural and functional outcomes after stroke.
Authors: Piotr Walczak; Jian Zhang; Assaf A Gilad; Dorota A Kedziorek; Jesus Ruiz-Cabello; Randell G Young; Mark F Pittenger; Peter C M van Zijl; Judy Huang; Jeff W M Bulte Journal: Stroke Date: 2008-03-06 Impact factor: 7.914
Authors: Uwe M Fischer; Matthew T Harting; Fernando Jimenez; Werner O Monzon-Posadas; Hasen Xue; Sean I Savitz; Glen A Laine; Charles S Cox Journal: Stem Cells Dev Date: 2009-06 Impact factor: 3.272
Authors: Lian Li; Quan Jiang; Guangliang Ding; Li Zhang; Zheng Gang Zhang; Qingjiang Li; Swayamprava Panda; Mei Lu; James R Ewing; Michael Chopp Journal: J Cereb Blood Flow Metab Date: 2009-11-04 Impact factor: 6.200
Authors: Bing Yang; Roger Strong; Sushil Sharma; Miranda Brenneman; Kasam Mallikarjunarao; Xiaopei Xi; James C Grotta; Jaroslaw Aronowski; Sean I Savitz Journal: J Neurosci Res Date: 2011-03-15 Impact factor: 4.164
Authors: Joshua Y Chua; Arjun V Pendharkar; Nancy Wang; Raymond Choi; Robert H Andres; Xavier Gaeta; Jian Zhang; Mike E Moseley; Raphael Guzman Journal: J Cereb Blood Flow Metab Date: 2010-12-15 Impact factor: 6.200
Authors: Martina Vendrame; Carmelina Gemma; Keith R Pennypacker; Paula C Bickford; Cyndy Davis Sanberg; Paul R Sanberg; Alison E Willing Journal: Exp Neurol Date: 2006-05-19 Impact factor: 5.330
Authors: Sean I Savitz; Vivek Misra; Mallik Kasam; Harrinder Juneja; Charles S Cox; Susan Alderman; Imo Aisiku; Siddhartha Kar; Adrian Gee; James C Grotta Journal: Ann Neurol Date: 2011-07 Impact factor: 10.422
Authors: Miranda Brenneman; Sushil Sharma; Matthew Harting; Roger Strong; Charles S Cox; Jarek Aronowski; James C Grotta; Sean I Savitz Journal: J Cereb Blood Flow Metab Date: 2009-09-23 Impact factor: 6.200
Authors: Martina Vendrame; Jordan Cassady; Jennifer Newcomb; Tanya Butler; Keith R Pennypacker; Tanja Zigova; Cyndy Davis Sanberg; Paul R Sanberg; Alison E Willing Journal: Stroke Date: 2004-08-19 Impact factor: 7.914
Authors: Farhaan S Vahidy; Mohammad H Rahbar; Hongjian Zhu; Paul J Rowan; Arvind B Bambhroliya; Sean I Savitz Journal: Stroke Date: 2016-05-10 Impact factor: 7.914
Authors: Piotr Walczak; Joanna Wojtkiewicz; Adam Nowakowski; Aleksandra Habich; Piotr Holak; Jiadi Xu; Zbigniew Adamiak; Moussa Chehade; Monica S Pearl; Philippe Gailloud; Barbara Lukomska; Wojciech Maksymowicz; Jeff Wm Bulte; Miroslaw Janowski Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200